Patients with de novo or secondary acute myeloid leukemia (AML) - intermediate or high risk according to European LeukemiaNet (ELN) recommendations 2017
Untreated patients at diagnosis of acute myeloid leukemia - patients may have received treatment for high-risk myelodysplastic syndromes with hypomethylating agents (HMA). They should not have received a course of induction chemotherapy to be eligible for this study
Haploidentical family stem cell donor or other suitable donors available
Fit and unfit patients by geriatric scale assessment
Signed informed consent.
You may not be if
Acute Myeloid Leukemia good risk according to European LeukemiaNet 2017
Positive serology for Human Immunodeficiency Virus.
Serious organ dysfunction: left ventricular ejection fraction \< 40%, forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) \<50% of predicted, Liver Function Tests \> 5 x the upper limit of normal, or creatinine clearance \<30 ml/min .
Life expectancy less than 30 days.
Frail patients by geriatric scale assessment
Clareo Health | Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
